CDx
Contact Us

Therapeutic Modalities

Get Started
Scientist working in a CellCarta laboratory supporting ADC, cell therapy, and targeted protein degrader programs

Drive Your Discovery Forward

Access tailored support for your therapeutic programs, from ADCs and cell therapies to targeted protein degraders. In-depth analysis is delivered by scientific teams with a deep understanding of your therapeutic modality.

25+ Years of expertise
8 Global labs
750+ Employees

Explore the Therapeutic Modalities We Support

Antibody-Drug Conjugate research scientist performing precision biomarker assays for target engagement and TME profiling

Antibody-Drug Conjugates (ADC)

Precision assays for target engagement, pharmacokinetics, and TME profiling.

Cell therapy biomarker scientist supporting comprehensive immunophenotyping and cell therapy approval programs

Cell Therapy

Custom assays for cell therapy proliferation kinetics, phenotypic state, and target cell depletion.

Scientist developing specialized assays for targeted protein degrader potency, dosing, and resistance assessment

Targeted Protein Degraders

Specialized assays for understanding TDP potency, dosing, and resistance.

Why CellCarta

We deliver the depth and rigor that ADC, cell therapy, and TPD programs demand.

Modality-Specific Expertise

Multi-Omic Capabilities

Global Execution

Custom Assay Design

CAP/CLIA Accredited Labs

CellCarta Combining High Plex Proteomics With Single Cell Transcriptomics For Deep Characterization EN Final

Case Study

T Cell Multi-Omics

CellCarta combined high-plex proteomics with single-cell transcriptomics to characterize antigen-specific T cell responses. Through this integrated workflow, T-cell activation can be investigated as a clinical biomarker for CAR-T therapies, TCE programs, and other immunotherapies.

Need Support for Your Program?

Tell us about your needs, and our scientific team will help identify the right approach for your therapeutic modality program.

Gloved hands staining slides in a tray.